XMD17-109 | B1685

XMD17-109 is a novel, specific ERK-5 inhibitor, which inhibits the ERK5-mediated AP1 transcriptional activity at 30 μM, and has an EC50 of 4.2 μM.

XMD17-109 is a novel, specific ERK-5 inhibitor, which inhibits the ERK5-mediated AP1 transcriptional activity at 30 μM, and has an EC50 of 4.2 μM.

B1685 | XMD17-109 DataSheet

Alternate Name/Synonyms: XMD17-109; XMD17 109; XMD17109; 11-cyclopentyl-2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one

Appearance: Solid

Formulation: N/A

CAS Number: 1435488-37-1

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₃₆H₄₆N₈O₃

Molecular Weight: 638.8

Cell-Permeable?: Yes

Purity: >98%

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A ERK-5 inhibitor

MDL Number: NA

PubChem CID: 71604307

SMILES: CCOC1=C(C=CC(=C1)C(=O)N2CCC(CC2)N3CCN(CC3)C)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C7CCCC7

InChi: InChI=1S/C36H46N8O3/c1-4-47-32-23-25(34(45)43-17-15-26(16-18-43)42-21-19-40(2)20-22-42)13-14-29(32)38-36-37-24-31-33(39-36)44(27-9-5-6-10-27)30-12-8-7-11-28(30)35(46)41(31)3/h7-8,11-14,23-24,26-27H,4-6,9-10,15-22H2,1-3H3,(H,37,38,39)

InChi Key: XVBGRTMNFNMINE-UHFFFAOYSA-N